Skip to content
Try Mental Wellness – Lifestyle
Author:
Sensorium Therapeutics
Sensorium Therapeutics Announces Positive Phase 1a Data for SNTX-2643 Showing Rapid and Sustained CNS Pharmacodynamic Activity
September 21, 2026
Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026
August 19, 2026